October 27th, 2014
This week’s topics include behavioral counseling for those with CV risk factors, long-term outcomes after stenting vs. endarterectomy for treatment of symptomatic carotid stenosis, and more.
February 25th, 2011
The FDA has approved azilsartan medoxomil (Edarbi, Takeda) for the treatment of high blood pressure. The new angiotensin II receptor blocker (ARB) will be available in 80 mg and 40 mg doses. The recommended dose is 80 mg once daily. The 40 mg dose is used in combination with a diuretic. The FDA said that, in clinical studies, […]